Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes (Q36419244)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes (English)

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

1 reference

based on heuristic

inferred from title

Federico Pregheffi

10

object named as

Federico Garrido

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Francesco Marincola

9

object named as

Francesco M Marincola

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

author name string

Rafael Carretero

1

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Ena Wang

2

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Ana I Rodriguez

3

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Jennifer Reinboth

4

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Maria L Ascierto

5

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Alyson M Engle

6

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Hui Liu

7

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Francisco M Camacho

8

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Teresa Cabrera

11

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

language of work or name

0 references

publication date

9 November 2011

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

International Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

131

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

2

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

387-395

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Therapeutic cancer vaccines: are we there yet?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504975

30 September 2017

"Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504975

30 September 2017

Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504975

30 September 2017

Analysis of gene expression data using BRB-ArrayTools.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504975

30 September 2017

Adoptive cell therapy for the treatment of patients with metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504975

30 September 2017

Next generation of immunotherapy for melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504975

30 September 2017

Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504975

30 September 2017

The immunologic constant of rejection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504975

30 September 2017

Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504975

30 September 2017

Vaccine therapy for melanoma: current status and future directions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504975

30 September 2017

Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504975

30 September 2017

Mechanisms of immune evasion by tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504975

30 September 2017

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504975

30 September 2017

M-Vax: an autologous, hapten-modified vaccine for human cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504975

30 September 2017

Cancer immunotherapy: moving beyond current vaccines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504975

30 September 2017

Selection and validation of endogenous reference genes using a high throughput approach

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504975

30 September 2017

Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504975

30 September 2017

MHC antigens and tumor escape from immune surveillance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504975

30 September 2017

Cluster analysis and display of genome-wide expression patterns

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504975

30 September 2017

Natural history of HLA expression during tumour development.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504975

30 September 2017

Implications for immunosurveillance of altered HLA class I phenotypes in human tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504975

30 September 2017

Therapeutic vaccination for cancer immunotherapy: Antigen selection and clinical responses

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26471

21 January 2018

HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26471

21 January 2018

Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26471

21 January 2018

High-fidelity mRNA amplification for gene profiling.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3504975

21 September 2018

A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26471

21 January 2018

Analysis of independent microarray datasets of renal biopsies identifies a robust transcript signature of acute allograft rejection

1 reference

https://pubmed.ncbi.nlm.nih.gov/21964766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21964766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/IJC.26471

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36419244&oldid=1630253523"